In denying Pfizer’s motion to enjoin a lawsuit, a federal judge has said it is up to a jury to decide whether diet drugs caused a South Carolina woman’s likely fatal pulmonary hypertension to surface 11 years after she stopped taking the drugs.

Plaintiff’s counsel Michael D. Fishbein of Levin, Fishbein, Sedran & Berman said the intention of the motion by drugmaker Wyeth, now owned by Pfizer, “was to wipe out all of the federal cases.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]